Analysis of CareRA, early RA 330 pt trial shows long term outcomes linked to initial response type rather than regimen. Best PROMs in the 42% with early persistent response. 9% were primary NR, 28% secondary NR, 21% delayed responders. https://t.co/ZDqYD3krtb